Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

AstraZeneca

Status: Completed

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT01817569

EUPAS19606 (Registry Identifier)

D5550C00001

Details and patient eligibility

About

The purpose of this investigation is to describe general safety profile of type II Diabetes Mellitus (DM) Japanese patients under exenatide therapy in real world medical practices

Full description

Specific Clinical Experience Investigation for long-term use of exenatide (Byetta subcutaneous injection).

Enrollment: 2,948 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patient diagnosed with Type 2 Diabetes Mellitus and who is naive patient with Byetta.

Trial design

2,948 participants in 1 patient group

Byetta